| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 16 | 2025 | 213 | 2.570 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 7 | 2025 | 55 | 1.780 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 8 | 2025 | 35 | 1.740 |
Why?
|
| Encephalitis | 8 | 2024 | 118 | 1.290 |
Why?
|
| Systemic Inflammatory Response Syndrome | 9 | 2025 | 199 | 1.250 |
Why?
|
| Status Epilepticus | 7 | 2025 | 157 | 1.220 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 5 | 2017 | 14 | 1.140 |
Why?
|
| Brain Diseases | 4 | 2022 | 306 | 1.110 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 3 | 2012 | 22 | 1.060 |
Why?
|
| Seizures, Febrile | 5 | 2025 | 31 | 1.000 |
Why?
|
| Immunotherapy | 9 | 2025 | 749 | 1.000 |
Why?
|
| Rheumatology | 8 | 2024 | 129 | 0.890 |
Why?
|
| Antiphospholipid Syndrome | 3 | 2010 | 25 | 0.860 |
Why?
|
| Child | 60 | 2025 | 25783 | 0.810 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2022 | 149 | 0.810 |
Why?
|
| Drug Resistant Epilepsy | 6 | 2025 | 235 | 0.780 |
Why?
|
| Central Nervous System Diseases | 2 | 2021 | 109 | 0.770 |
Why?
|
| Psychotic Disorders | 3 | 2017 | 150 | 0.740 |
Why?
|
| Autoantibodies | 7 | 2024 | 457 | 0.730 |
Why?
|
| Hashimoto Disease | 4 | 2024 | 29 | 0.720 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2021 | 54 | 0.720 |
Why?
|
| Autoimmune Diseases of the Nervous System | 5 | 2025 | 36 | 0.710 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2021 | 11 | 0.710 |
Why?
|
| Immunoglobulins, Intravenous | 5 | 2024 | 150 | 0.670 |
Why?
|
| Dexamethasone | 4 | 2025 | 273 | 0.650 |
Why?
|
| Plasma Exchange | 2 | 2018 | 88 | 0.620 |
Why?
|
| Brain | 9 | 2023 | 3183 | 0.610 |
Why?
|
| Autoimmune Diseases | 4 | 2024 | 272 | 0.600 |
Why?
|
| Pneumonia | 1 | 2022 | 334 | 0.580 |
Why?
|
| Neurodegenerative Diseases | 1 | 2021 | 280 | 0.570 |
Why?
|
| Adolescent | 39 | 2025 | 20557 | 0.540 |
Why?
|
| Cytokines | 1 | 2023 | 1365 | 0.510 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2022 | 56 | 0.500 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2024 | 3844 | 0.500 |
Why?
|
| Cognition Disorders | 5 | 2017 | 569 | 0.500 |
Why?
|
| Humans | 80 | 2025 | 132201 | 0.490 |
Why?
|
| Central Nervous System | 2 | 2021 | 283 | 0.490 |
Why?
|
| Epilepsy | 2 | 2021 | 891 | 0.420 |
Why?
|
| Cerebrum | 2 | 2010 | 38 | 0.410 |
Why?
|
| Stroke | 4 | 2011 | 1083 | 0.400 |
Why?
|
| Polyarteritis Nodosa | 1 | 2012 | 8 | 0.390 |
Why?
|
| Encephalitis, Herpes Simplex | 2 | 2025 | 13 | 0.390 |
Why?
|
| Neuropsychological Tests | 5 | 2017 | 990 | 0.380 |
Why?
|
| Female | 47 | 2025 | 70754 | 0.380 |
Why?
|
| Male | 44 | 2025 | 64979 | 0.380 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2012 | 10 | 0.370 |
Why?
|
| Bone Marrow Transplantation | 1 | 2015 | 611 | 0.370 |
Why?
|
| Brain Edema | 1 | 2012 | 70 | 0.370 |
Why?
|
| Glucocorticoids | 5 | 2023 | 387 | 0.360 |
Why?
|
| Cerebral Ventricles | 1 | 2012 | 82 | 0.360 |
Why?
|
| Streptococcal Infections | 2 | 2024 | 248 | 0.350 |
Why?
|
| Quinolones | 1 | 2011 | 58 | 0.340 |
Why?
|
| Nervous System Diseases | 2 | 2018 | 411 | 0.340 |
Why?
|
| Pediatrics | 5 | 2024 | 1210 | 0.340 |
Why?
|
| ADAM Proteins | 1 | 2011 | 84 | 0.340 |
Why?
|
| Epileptic Syndromes | 2 | 2021 | 33 | 0.330 |
Why?
|
| Cerebral Hemorrhage | 1 | 2012 | 158 | 0.330 |
Why?
|
| Lupus Nephritis | 3 | 2017 | 43 | 0.330 |
Why?
|
| Immunosuppressive Agents | 6 | 2017 | 673 | 0.330 |
Why?
|
| Antibodies, Antiphospholipid | 4 | 2011 | 20 | 0.330 |
Why?
|
| Granulomatosis with Polyangiitis | 4 | 2016 | 34 | 0.320 |
Why?
|
| Cerebellum | 2 | 2010 | 462 | 0.310 |
Why?
|
| Immunologic Factors | 3 | 2021 | 184 | 0.310 |
Why?
|
| Mentoring | 2 | 2024 | 83 | 0.310 |
Why?
|
| Piperazines | 1 | 2011 | 255 | 0.310 |
Why?
|
| Rituximab | 5 | 2024 | 167 | 0.310 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2010 | 289 | 0.300 |
Why?
|
| Anticoagulants | 3 | 2010 | 610 | 0.300 |
Why?
|
| Electroencephalography | 3 | 2024 | 908 | 0.300 |
Why?
|
| Program Evaluation | 2 | 2024 | 456 | 0.290 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2024 | 305 | 0.290 |
Why?
|
| Neutropenia | 2 | 2021 | 205 | 0.280 |
Why?
|
| Child, Preschool | 19 | 2025 | 14735 | 0.270 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2007 | 7 | 0.270 |
Why?
|
| Pneumonia, Viral | 2 | 2022 | 390 | 0.260 |
Why?
|
| Retrospective Studies | 17 | 2025 | 17391 | 0.250 |
Why?
|
| Microscopic Polyangiitis | 3 | 2016 | 14 | 0.240 |
Why?
|
| Diagnosis, Differential | 7 | 2025 | 1962 | 0.240 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2025 | 8 | 0.240 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 170 | 0.230 |
Why?
|
| Inflammation | 4 | 2023 | 1520 | 0.230 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2024 | 831 | 0.230 |
Why?
|
| Thrombosis | 1 | 2010 | 525 | 0.230 |
Why?
|
| Typhus, Endemic Flea-Borne | 1 | 2025 | 28 | 0.220 |
Why?
|
| Quality Improvement | 2 | 2024 | 700 | 0.220 |
Why?
|
| Mental Health Services | 2 | 2019 | 281 | 0.220 |
Why?
|
| Clinical Protocols | 1 | 2025 | 239 | 0.210 |
Why?
|
| B-Lymphocytes | 2 | 2024 | 543 | 0.210 |
Why?
|
| Microglia | 1 | 2025 | 138 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2025 | 559 | 0.200 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 32 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2025 | 155 | 0.200 |
Why?
|
| Chorea | 1 | 2023 | 38 | 0.200 |
Why?
|
| Cohort Studies | 10 | 2021 | 5173 | 0.190 |
Why?
|
| Hemorrhage | 2 | 2016 | 519 | 0.190 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2025 | 305 | 0.190 |
Why?
|
| Lung Diseases | 2 | 2016 | 408 | 0.190 |
Why?
|
| Infant | 10 | 2025 | 13048 | 0.190 |
Why?
|
| Adult | 13 | 2025 | 31600 | 0.180 |
Why?
|
| Gastrointestinal Diseases | 1 | 2025 | 356 | 0.180 |
Why?
|
| Injection Site Reaction | 1 | 2021 | 7 | 0.170 |
Why?
|
| Prednisolone | 1 | 2021 | 73 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 298 | 0.170 |
Why?
|
| Platelet Count | 1 | 2021 | 139 | 0.170 |
Why?
|
| Remission Induction | 2 | 2012 | 306 | 0.170 |
Why?
|
| Methylprednisolone | 1 | 2021 | 98 | 0.170 |
Why?
|
| Depression | 1 | 2009 | 1350 | 0.170 |
Why?
|
| Europe | 3 | 2017 | 373 | 0.170 |
Why?
|
| Mentors | 3 | 2024 | 164 | 0.170 |
Why?
|
| Injections, Spinal | 3 | 2025 | 135 | 0.170 |
Why?
|
| Nephrotic Syndrome | 2 | 2021 | 51 | 0.170 |
Why?
|
| Hyperglycemia | 1 | 2022 | 235 | 0.170 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 330 | 0.160 |
Why?
|
| Cat-Scratch Disease | 1 | 2020 | 30 | 0.160 |
Why?
|
| Anaphylaxis | 1 | 2021 | 87 | 0.160 |
Why?
|
| Blood Pressure | 1 | 2025 | 1402 | 0.160 |
Why?
|
| Parents | 2 | 2024 | 1080 | 0.160 |
Why?
|
| Aspirin | 1 | 2021 | 220 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2021 | 338 | 0.150 |
Why?
|
| Social Workers | 1 | 2019 | 5 | 0.150 |
Why?
|
| Meningoencephalitis | 1 | 2019 | 22 | 0.150 |
Why?
|
| Psychology | 1 | 2019 | 58 | 0.150 |
Why?
|
| Metal Metabolism, Inborn Errors | 1 | 2018 | 7 | 0.150 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2019 | 114 | 0.150 |
Why?
|
| Ischemic Attack, Transient | 2 | 2010 | 64 | 0.150 |
Why?
|
| Biomedical Research | 2 | 2015 | 554 | 0.150 |
Why?
|
| United States | 9 | 2024 | 11675 | 0.150 |
Why?
|
| Treatment Outcome | 9 | 2025 | 13028 | 0.140 |
Why?
|
| West Nile Fever | 1 | 2020 | 139 | 0.140 |
Why?
|
| Arthralgia | 1 | 2018 | 68 | 0.140 |
Why?
|
| Surveys and Questionnaires | 7 | 2024 | 3995 | 0.140 |
Why?
|
| Canada | 4 | 2024 | 337 | 0.140 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2023 | 149 | 0.140 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2017 | 14 | 0.140 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2017 | 62 | 0.140 |
Why?
|
| Antipsychotic Agents | 2 | 2011 | 381 | 0.130 |
Why?
|
| Disease Management | 1 | 2021 | 565 | 0.130 |
Why?
|
| Cytoskeletal Proteins | 1 | 2018 | 282 | 0.130 |
Why?
|
| Sepsis | 1 | 2021 | 516 | 0.130 |
Why?
|
| Neurologists | 1 | 2017 | 27 | 0.130 |
Why?
|
| Algorithms | 3 | 2020 | 1723 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2022 | 379 | 0.130 |
Why?
|
| Hypertension | 1 | 2025 | 1398 | 0.130 |
Why?
|
| Psychotropic Drugs | 1 | 2017 | 129 | 0.130 |
Why?
|
| Interinstitutional Relations | 1 | 2016 | 21 | 0.130 |
Why?
|
| Cyclophosphamide | 3 | 2016 | 426 | 0.130 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 2 | 2016 | 30 | 0.130 |
Why?
|
| Disease Progression | 1 | 2023 | 2230 | 0.120 |
Why?
|
| Astrocytes | 1 | 2019 | 269 | 0.120 |
Why?
|
| Adolescent Health Services | 1 | 2016 | 34 | 0.120 |
Why?
|
| Health Surveys | 1 | 2017 | 260 | 0.120 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 3091 | 0.120 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 153 | 0.120 |
Why?
|
| Adolescent Behavior | 1 | 2017 | 171 | 0.120 |
Why?
|
| Child Behavior | 1 | 2017 | 236 | 0.120 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 587 | 0.120 |
Why?
|
| Basement Membrane | 1 | 2015 | 47 | 0.120 |
Why?
|
| Young Adult | 6 | 2025 | 9965 | 0.110 |
Why?
|
| Churg-Strauss Syndrome | 2 | 2012 | 20 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 5410 | 0.110 |
Why?
|
| Weight Gain | 2 | 2022 | 381 | 0.110 |
Why?
|
| Anemia, Aplastic | 1 | 2015 | 60 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 623 | 0.110 |
Why?
|
| Vasculitis | 2 | 2012 | 50 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 63 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 247 | 0.110 |
Why?
|
| Glomerulonephritis | 2 | 2011 | 74 | 0.100 |
Why?
|
| Mental Disorders | 2 | 2024 | 893 | 0.100 |
Why?
|
| Quality of Life | 2 | 2025 | 2161 | 0.100 |
Why?
|
| Dyskinesias | 1 | 2013 | 19 | 0.100 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2012 | 21 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1304 | 0.100 |
Why?
|
| Prevalence | 2 | 2010 | 2663 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 144 | 0.100 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2012 | 23 | 0.090 |
Why?
|
| Cognition | 1 | 2017 | 811 | 0.090 |
Why?
|
| Physicians | 2 | 2016 | 640 | 0.090 |
Why?
|
| Global Health | 1 | 2017 | 644 | 0.090 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2012 | 153 | 0.090 |
Why?
|
| Aripiprazole | 1 | 2011 | 22 | 0.090 |
Why?
|
| Glomerular Basement Membrane | 1 | 2011 | 9 | 0.090 |
Why?
|
| Biomarkers | 2 | 2025 | 3402 | 0.090 |
Why?
|
| Risk Factors | 5 | 2018 | 10944 | 0.090 |
Why?
|
| Blood Cell Count | 2 | 2025 | 68 | 0.090 |
Why?
|
| Rheumatologists | 2 | 2022 | 7 | 0.090 |
Why?
|
| ADAMTS13 Protein | 1 | 2011 | 66 | 0.080 |
Why?
|
| Tertiary Care Centers | 2 | 2025 | 259 | 0.080 |
Why?
|
| Age of Onset | 3 | 2017 | 626 | 0.080 |
Why?
|
| Antirheumatic Agents | 1 | 2012 | 122 | 0.080 |
Why?
|
| Kidney | 1 | 2017 | 1338 | 0.080 |
Why?
|
| Movement Disorders | 1 | 2013 | 223 | 0.080 |
Why?
|
| Stroke Volume | 2 | 2023 | 536 | 0.080 |
Why?
|
| Radiography | 1 | 2012 | 819 | 0.080 |
Why?
|
| Autoimmunity | 1 | 2011 | 181 | 0.080 |
Why?
|
| Atrophy | 1 | 2010 | 251 | 0.080 |
Why?
|
| Ventricular Function, Left | 2 | 2023 | 548 | 0.080 |
Why?
|
| Immune System Diseases | 2 | 2021 | 52 | 0.080 |
Why?
|
| Reference Values | 1 | 2010 | 703 | 0.070 |
Why?
|
| Executive Function | 1 | 2009 | 127 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2010 | 137 | 0.070 |
Why?
|
| Aftercare | 2 | 2022 | 155 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 953 | 0.070 |
Why?
|
| Dyslipidemias | 1 | 2011 | 241 | 0.070 |
Why?
|
| Registries | 2 | 2012 | 1591 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2025 | 1177 | 0.070 |
Why?
|
| Consensus | 2 | 2021 | 658 | 0.070 |
Why?
|
| Age Factors | 2 | 2012 | 2920 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2010 | 571 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2024 | 1499 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2025 | 2313 | 0.060 |
Why?
|
| Warfarin | 1 | 2007 | 128 | 0.060 |
Why?
|
| C-Reactive Protein | 2 | 2023 | 464 | 0.060 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2025 | 7 | 0.060 |
Why?
|
| Scrub Typhus | 1 | 2025 | 11 | 0.060 |
Why?
|
| Seizures | 2 | 2023 | 895 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2009 | 779 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2008 | 185 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 2165 | 0.060 |
Why?
|
| Pandemics | 2 | 2022 | 1186 | 0.060 |
Why?
|
| Mutation | 1 | 2018 | 6243 | 0.050 |
Why?
|
| Glutamate Decarboxylase | 1 | 2024 | 42 | 0.050 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 125 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2025 | 3414 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 663 | 0.050 |
Why?
|
| Job Satisfaction | 1 | 2024 | 99 | 0.050 |
Why?
|
| Spin Labels | 1 | 2023 | 21 | 0.050 |
Why?
|
| Texas | 2 | 2025 | 3632 | 0.050 |
Why?
|
| Multiple Sclerosis | 2 | 2021 | 382 | 0.050 |
Why?
|
| Prognosis | 2 | 2025 | 5015 | 0.050 |
Why?
|
| Phenotype | 2 | 2025 | 4538 | 0.050 |
Why?
|
| Psychotherapy | 1 | 2024 | 247 | 0.050 |
Why?
|
| Blood Component Removal | 1 | 2021 | 35 | 0.040 |
Why?
|
| Methotrexate | 2 | 2016 | 350 | 0.040 |
Why?
|
| Potassium | 1 | 2022 | 275 | 0.040 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2021 | 18 | 0.040 |
Why?
|
| Time Factors | 2 | 2022 | 6452 | 0.040 |
Why?
|
| Long Term Adverse Effects | 1 | 2021 | 13 | 0.040 |
Why?
|
| Infectious Encephalitis | 1 | 2020 | 4 | 0.040 |
Why?
|
| Cannabidiol | 1 | 2021 | 21 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 296 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 120 | 0.040 |
Why?
|
| Agammaglobulinemia | 1 | 2021 | 44 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 322 | 0.040 |
Why?
|
| Diet, Ketogenic | 1 | 2021 | 25 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2025 | 937 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 240 | 0.040 |
Why?
|
| Immunization | 1 | 2021 | 312 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 279 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 674 | 0.040 |
Why?
|
| Reference Standards | 2 | 2010 | 242 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 539 | 0.040 |
Why?
|
| Data Collection | 1 | 2021 | 391 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2016 | 1444 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2009 | 6569 | 0.040 |
Why?
|
| Middle Aged | 3 | 2025 | 29007 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 511 | 0.040 |
Why?
|
| Rehabilitation | 1 | 2018 | 23 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2016 | 767 | 0.040 |
Why?
|
| Communicable Diseases | 1 | 2020 | 160 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2022 | 861 | 0.030 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2017 | 43 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2021 | 1255 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2007 | 3736 | 0.030 |
Why?
|
| Lymphoma | 1 | 2021 | 331 | 0.030 |
Why?
|
| Patient Care Management | 1 | 2017 | 66 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 1461 | 0.030 |
Why?
|
| Azathioprine | 1 | 2016 | 38 | 0.030 |
Why?
|
| Dizziness | 1 | 1996 | 27 | 0.030 |
Why?
|
| Hearing Disorders | 1 | 1996 | 29 | 0.030 |
Why?
|
| Immunologic Tests | 1 | 2016 | 17 | 0.030 |
Why?
|
| Medical Records, Problem-Oriented | 1 | 2016 | 10 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2016 | 33 | 0.030 |
Why?
|
| Tinnitus | 1 | 1996 | 23 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1996 | 105 | 0.030 |
Why?
|
| Vaccination | 1 | 2022 | 1018 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2016 | 57 | 0.030 |
Why?
|
| Asia | 1 | 2016 | 126 | 0.030 |
Why?
|
| Proteinuria | 1 | 2016 | 111 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2016 | 111 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2016 | 93 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2679 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2018 | 329 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 2138 | 0.030 |
Why?
|
| Syndrome | 1 | 2018 | 1175 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 437 | 0.030 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2015 | 20 | 0.030 |
Why?
|
| Antibodies, Antinuclear | 1 | 2015 | 31 | 0.030 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2015 | 41 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 295 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 321 | 0.030 |
Why?
|
| Psychometrics | 1 | 2018 | 693 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2015 | 216 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 2015 | 218 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2017 | 374 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2016 | 292 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 333 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 600 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 203 | 0.030 |
Why?
|
| Curriculum | 1 | 2018 | 765 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 826 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 821 | 0.020 |
Why?
|
| Animals | 2 | 2015 | 34842 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 2553 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 547 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2016 | 325 | 0.020 |
Why?
|
| Logistic Models | 1 | 2017 | 1841 | 0.020 |
Why?
|
| Blood Sedimentation | 1 | 2012 | 29 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 803 | 0.020 |
Why?
|
| Tremor | 1 | 2013 | 136 | 0.020 |
Why?
|
| Brain Injuries | 1 | 1996 | 716 | 0.020 |
Why?
|
| Headache | 1 | 2011 | 110 | 0.020 |
Why?
|
| Mass Screening | 1 | 2016 | 830 | 0.020 |
Why?
|
| DNA | 1 | 2015 | 1479 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2016 | 948 | 0.020 |
Why?
|
| Hospitalization | 1 | 2018 | 1902 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2018 | 1258 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8548 | 0.020 |
Why?
|
| Aging | 1 | 2014 | 1251 | 0.020 |
Why?
|
| Aged | 1 | 2025 | 21456 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 4758 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 3015 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4690 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 18504 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1996 | 212 | 0.010 |
Why?
|